Form 4: Intellia Therapeutics Director Sells Shares Under Pre-Arranged Trading Plan

Intellia Therapeutics Director Jesse Goodman sold 3,094 shares of common stock in late June and early July 2025, pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Jesse Goodman, a Director of Intellia Therapeutics, Inc. (NTLA), reported the sale of 3,094 shares of common stock.
• The sales occurred in two separate transactions: 1,547 shares on June 30, 2025, and another 1,547 shares on July 1, 2025.
• The shares sold on June 30, 2025, were at a price of $9.56 per share.
• The shares sold on July 1, 2025, were at a price of $9.23 per share.
• Following these transactions, Jesse Goodman beneficially owns 24,359 shares of Intellia Therapeutics common stock.
• The sales were executed automatically pursuant to a Rule 10b5-1 trading plan adopted by Jesse Goodman on March 31, 2025.

Sentiment

Score: 5

Explanation: The sentiment is neutral. This is a routine disclosure of an insider stock sale conducted under a pre-arranged 10b5-1 plan, which is a common and expected event for corporate insiders. While it's a sale, the pre-planned nature mitigates negative interpretations.

Positives

• The sales were conducted under a Rule 10b5-1 trading plan, which indicates the transactions were pre-scheduled and not based on material non-public information, enhancing transparency and mitigating concerns about opportunistic insider selling.

Negatives

• A director selling shares, even under a 10b5-1 plan, can sometimes be perceived as a lack of confidence in the company's near-term prospects, although this is often a routine part of personal financial planning.
• The sale prices of $9.56 and $9.23 per share are relatively low, which could be seen as a negative signal regarding the stock's valuation at the time of sale.

Risks

• No specific risks are detailed in this Form 4 filing beyond the general market perception associated with insider selling, even when conducted under a 10b5-1 plan.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The reported sale of 3,094 shares on this Form 4 occurred automatically pursuant to a 10b5-1 trading plan adopted by the reporting person on March 31, 2025.

Industry Context

This specific Form 4 filing, detailing an insider stock transaction, does not provide broader industry trends or competitive analysis. It is a company-specific disclosure related to an individual's stock holdings.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan for insider stock sales is a standard corporate governance practice in the U.S. to mitigate concerns about insider trading based on non-public information. Many executives and directors at publicly traded companies, including those in the biotechnology sector like Intellia Therapeutics, utilize such plans for their personal stock transactions.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a director could be viewed with slight caution, but the execution under a 10b5-1 plan generally reassures investors that the transaction is for personal financial planning rather than a signal of negative company performance. The reduction in director's direct ownership is minor relative to total shares outstanding.

Next Steps

• No specific future actions or milestones for the company are mentioned in this Form 4 filing.

Key Dates

Keywords

Intellia Therapeutics, NTLA, Form 4, insider trading, stock sale, 10b5-1 plan, Jesse Goodman, director, common stock